Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

657
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
657
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

613
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
613
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

725
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
725
Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

605
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
605
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

912
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
912
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy01:30

Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy

1.0K
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
1.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Patients with Ileal Pouch-Anal Anastomosis Have Decreased Bowel Frequency on Glucagon-like Peptide-1 Receptor Agonist Therapy.

Clinical and translational gastroenterology·2026
Same author

Inflamed Skin and Bones: SAPHO Syndrome in a Patient with Indeterminate Colitis.

Digestive diseases and sciences·2026
Same author

MUSings on a Crohn's Disease Diagnosis.

Digestive diseases and sciences·2025
Same author

A Prospective Comparison of Ustekinumab and Antitumor Necrosis Factor α Therapy in the Treatment of Crohn's-Like Disease of the Pouch.

The American journal of gastroenterology·2025
Same author

HLA DQA1*05 and Risk of Antitumor Necrosis Factor Treatment Failure and Anti-Drug Antibody Development in Children With Crohn's Disease.

The American journal of gastroenterology·2025
Same author

Understanding the Lived Experience After Colectomy and Ileal Pouch-Anal Anastomosis for Ulcerative Colitis: A Qualitative Study.

Crohn's & colitis 360·2025
Same journal

Pancreatitis in Familial Dysautonomia Patients.

Digestive diseases (Basel, Switzerland)·2026
Same journal

Treatment outcomes with empirical Clarithromycin-based triple therapy for Helicobacter pylori in Zambia, sub-Saharan Africa.

Digestive diseases (Basel, Switzerland)·2026
Same journal

Endoscopic submucosal dissection-associated bacteremia: proper antibiotic management.

Digestive diseases (Basel, Switzerland)·2026
Same journal

The investigation and treatment of Helicobacter pylori for the prevention of gastric cancer: A narrative review and assessment of management approaches.

Digestive diseases (Basel, Switzerland)·2026
Same journal

Analysis of Helicobacter pylori resistance and its trends in Chongqing: A 10-year retrospective study.

Digestive diseases (Basel, Switzerland)·2026
Same journal

Early-onset colorectal cancer in Australia: environmental, microbial, and policy implications.

Digestive diseases (Basel, Switzerland)·2026
See all related articles

Related Experiment Video

Updated: Mar 24, 2026

Therapeutic Evaluation of Fecal Microbiota Transplantation in an Interleukin 10-Deficient Mouse Model
05:41

Therapeutic Evaluation of Fecal Microbiota Transplantation in an Interleukin 10-Deficient Mouse Model

Published on: April 6, 2022

3.6K

Methotrexate for Inflammatory Bowel Diseases - New Developments.

Hans H Herfarth1

  • 1Division of Gastroenterology and Hepatology, Department of Medicine, University of North Carolina, Chapel Hill, N.C., USA.

Digestive Diseases (Basel, Switzerland)
|March 17, 2016
PubMed
Summary
This summary is machine-generated.

Methotrexate (MTX) is a key treatment for Crohn's disease (CD) and is used with anti-TNF therapies. Newer research suggests MTX may also be effective for ulcerative colitis (UC), challenging previous assumptions.

More Related Videos

Fluorescence-mediated Tomography for the Detection and Quantification of Macrophage-related Murine Intestinal Inflammation
07:05

Fluorescence-mediated Tomography for the Detection and Quantification of Macrophage-related Murine Intestinal Inflammation

Published on: December 15, 2017

8.8K
Evaluating Therapeutic Interventions in the SHIP-deficient Mouse Model of Crohn Disease-like Ileitis and Fibrosis
09:44

Evaluating Therapeutic Interventions in the SHIP-deficient Mouse Model of Crohn Disease-like Ileitis and Fibrosis

Published on: October 14, 2025

582

Related Experiment Videos

Last Updated: Mar 24, 2026

Therapeutic Evaluation of Fecal Microbiota Transplantation in an Interleukin 10-Deficient Mouse Model
05:41

Therapeutic Evaluation of Fecal Microbiota Transplantation in an Interleukin 10-Deficient Mouse Model

Published on: April 6, 2022

3.6K
Fluorescence-mediated Tomography for the Detection and Quantification of Macrophage-related Murine Intestinal Inflammation
07:05

Fluorescence-mediated Tomography for the Detection and Quantification of Macrophage-related Murine Intestinal Inflammation

Published on: December 15, 2017

8.8K
Evaluating Therapeutic Interventions in the SHIP-deficient Mouse Model of Crohn Disease-like Ileitis and Fibrosis
09:44

Evaluating Therapeutic Interventions in the SHIP-deficient Mouse Model of Crohn Disease-like Ileitis and Fibrosis

Published on: October 14, 2025

582

Area of Science:

  • Gastroenterology
  • Pharmacology
  • Immunology

Background:

  • Methotrexate (MTX) is a standard treatment for steroid-dependent Crohn's disease (CD).
  • MTX is commonly combined with anti-TNF agents to prevent anti-drug antibody formation.
  • Historically, MTX was considered ineffective for ulcerative colitis (UC), but recent evidence suggests otherwise.

Purpose of the Study:

  • To review current data on the efficacy of Methotrexate in managing Inflammatory Bowel Diseases.
  • To evaluate the role of MTX in Crohn's disease (CD) and ulcerative colitis (UC).
  • To discuss the use of MTX in combination therapy with anti-TNF agents.

Main Methods:

  • Literature review of recent clinical studies and data.
  • Analysis of treatment outcomes for MTX in CD and UC patients.
  • Examination of studies involving combination therapy with anti-TNF agents.

Main Results:

  • MTX remains a vital therapy for steroid-dependent Crohn's disease.
  • Emerging data indicate potential clinical effectiveness of MTX in ulcerative colitis.
  • Combination therapy with MTX and anti-TNF agents is effective in preventing antibody formation.

Conclusions:

  • Methotrexate demonstrates established efficacy in Crohn's disease.
  • Recent findings support the consideration of MTX for ulcerative colitis treatment.
  • The combination of MTX with anti-TNF agents is a valuable strategy in IBD management.